de Baar M P, van Dooren M W, de Rooij E, Bakker M, van Gemen B, Goudsmit J, de Ronde A
Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, The Netherlands.
J Clin Microbiol. 2001 Apr;39(4):1378-84. doi: 10.1128/JCM.39.4.1378-1384.2001.
Because human immunodeficiency virus type 1 (HIV-1) subtypes and circulating recombinant forms (CRFs) are spreading rapidly worldwide and are becoming less confined to a geographical area, RNA assays that can detect and quantify all HIV-1 isolates reliably are in demand. We have developed a fast, real-time monitored RNA assay based on an isothermal nucleic acid sequence-based amplification technology that amplifies a part of the long terminal repeat region of the HIV-1 genome. Real-time detection was possible due to the addition of molecular beacons to the amplification reaction that was monitored in a fluorimeter with a thermostat. The lower level of detection of the assay was 10 HIV-1 RNA molecules per reaction, and the lower level of quantification was 100 copies of HIV-1 RNA with a dynamic range of linear quantification between 10(2) and 10(7) RNA molecules. All HIV-1 groups, subtypes, and CRFs could be detected and quantified with equal efficiency, including the group N isolate YBF30 and the group O isolate ANT70. To test the clinical utility of the assay, a series of 62 serum samples containing viruses that encompassed subtypes A through G and CRFs AE and AG of HIV-1 group M were analyzed, and these results were compared to the results of a commercially available assay. This comparison showed that the quantification results correlated highly (R(2) = 0.735) for those subtypes that could be well quantified by both assays (subtypes B, C, D, and F), whereas improved quantification was obtained for subtypes A and G and CRFs AE and AG. A retrospective study with six individuals infected with either a subtype A, B, C, or D or an AG isolate of HIV-1 group M, who were treated with highly active antiretroviral therapy, revealed that the assay was well suited to the monitoring of therapy effects. In conclusion, the newly developed real-time monitored HIV-1 assay is a fast and sensitive assay with a large dynamic range of quantification and is suitable for quantification of most if not all subtypes and groups of HIV-1.
由于1型人类免疫缺陷病毒(HIV-1)亚型和循环重组型(CRF)在全球迅速传播,且不再局限于某一地理区域,因此需要能够可靠地检测和定量所有HIV-1分离株的RNA检测方法。我们基于等温核酸序列扩增技术开发了一种快速、实时监测的RNA检测方法,该技术可扩增HIV-1基因组的长末端重复区域的一部分。由于在带有恒温器的荧光计中监测的扩增反应中添加了分子信标,因此可以进行实时检测。该检测方法的最低检测水平为每个反应10个HIV-1 RNA分子,最低定量水平为100拷贝的HIV-1 RNA,线性定量动态范围为10²至10⁷个RNA分子。所有HIV-1组、亚型和CRF都能以相同效率进行检测和定量,包括N组分离株YBF30和O组分离株ANT70。为了测试该检测方法的临床实用性,分析了一系列62份含有HIV-1 M组A至G亚型以及CRF AE和AG的病毒的血清样本,并将这些结果与市售检测方法的结果进行比较。该比较表明,对于两种检测方法都能很好定量的亚型(B、C、D和F亚型),定量结果高度相关(R² = 0.735),而对于A和G亚型以及CRF AE和AG则获得了更好的定量结果。一项对6名感染HIV-1 M组A、B、C或D亚型或AG分离株并接受高效抗逆转录病毒治疗的个体的回顾性研究表明,该检测方法非常适合监测治疗效果。总之,新开发的实时监测HIV-1检测方法是一种快速、灵敏的检测方法,具有较大的定量动态范围,适用于定量大多数(如果不是全部)HIV-1亚型和组。